000 05271cam a2200445Ii 4500
988 _aSpringer_Medicine_2017
999 _c95878
_d95878
_x1
001 95878
003 ES-MaUEC
005 20230102112726.0
006 m o d
007 cr cnu|||unuuu
008 170426s2017 sz a o 001 0 eng d
020 _a3319397087
_q(electronic bk.)
020 _a9783319397085
_q(electronic bk.)
020 _z3319397079
020 _z9783319397078
_q(print)
040 _aN$T
_cN$T
_dGW5XE
_dN$T
_dEBLCP
_dYDX
_dUAB
_dESU
_dAZU
_dUPM
_dCOO
_dOTZ
_dVT2
_dOCLCQ
_dIOG
_dU3W
_dES-MaUEC
_bspa
050 4 _aRJ416.L4
_b2017 EB
245 0 0 _aChildhood acute lymphoblastic leukemia
_cAjay Vora, editor.
264 1 _aCham, Switzerland
_bSpringer
_c2017.
300 _a1 recurso en línea (ix, 342 páginas)
_bilustraciones (algunas a color)
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
500 _aIncluye índice
500 _aSpringerLink
505 0 _aContributors; Chapter 1: Epidemiology and Etiology of Childhood ALL; 1.1 Introduction; 1.2 General Epidemiology; 1.3 Natural History; 1.4 Environmental Risk Factors; 1.4.1 Infectious Disease and Immune Stimulation; 1.4.2 Other Risk Factors; 1.5 Heritability of ALL; 1.6 High-Penetrance Genetic Predisposition; 1.6.1 Syndromes Where ALL Is a Dominant Cancer Phenotype; 1.6.2 Syndromes Where ALL Is Part of a Mixed Cancer Phenotype; 1.7 Low-Penetrance Genetic Predisposition; 1.8 Future Directions; References; Chapter 2: Clinical Presentation and Prognostic Factors.
505 8 _a2.1 Clinical Presentation2.1.1 Introduction; 2.1.2 Symptoms and Signs Related to Bone Marrow Involvement; 2.1.3 Symptoms and Signs Related to Extensive Bulk Disease; 2.1.4 Central Nervous System; 2.1.5 The Eye; 2.1.6 Genitourinary System; 2.1.7 Cardiovascular System; 2.1.8 The Skin; 2.1.9 Head and Neck; 2.1.10 Gastrointestinal System; 2.1.11 Hypercalcaemia; 2.1.12 Haemophagocytic Lymphohistiocytosis (HLH); 2.1.13 Aplastic Presentation; 2.1.14 Rare Presentations; 2.1.15 Asymptomatic Pancytopenia; 2.1.16 The Diagnostic Interval and Pathway; 2.1.17 Differential Diagnosis; 2.2 Laboratory Features.
505 8 _a2.2.1 Haematology2.2.2 Biochemistry; 2.2.3 Bone Marrow Aspirate; 2.2.4 Lumbar Puncture; 2.3 Diagnostic Workup; 2.4 Prognostic Factors; 2.5 Individual Prognostic Factors; 2.5.1 Age; 2.5.2 White Cell Count; 2.5.3 NCI Risk Score; 2.5.4 Gender; 2.5.5 CNS Disease; 2.5.6 Disease Bulk; 2.5.7 Immunophenotype; 2.5.8 Genetics; 2.5.9 Response to Treatment; References; Chapter 3: Diagnostic Flow Cytometry and Immunophenotypic Classification; 3.1 Introduction; 3.2 Immunophenotype of T-Lymphoblastic Leukemia/Lymphoma; 3.3 Early T-Cell Precursor ALL; 3.4 Immunophenotype of B-Lymphoblastic Leukemia/Lymphoma.
505 8 _a3.5 Acute Leukaemia of Ambiguous Lineage3.6 Antigen Expression: Correlation to Prognosis and Cytogenetics; 3.7 Extended Leukaemia Immunophenotyping; 3.8 Conclusions and Perspective; References; Chapter 4: Cytogenetics and Molecular Genetics; 4.1 Introduction; 4.2 Abnormality Detection Methodologies; 4.3 Chromosomal Abnormalities in BCP-ALL; 4.3.1 Favourable Risk Abnormalities; 4.3.1.1 High Hyperdiploidy; 4.3.1.2 t(12; 21)(p13; q22)/ETV6-RUNX1; 4.3.1.3 t(1; 19)(q23; p13)/TCF3-PBX1; 4.3.2 Poor-Risk Chromosomal Abnormalities; 4.3.2.1 t(9; 22)(q34; q11.1)/BCR-ABL1; 4.3.2.2 t(17; 19)(q22.
505 8 _aP13)/TCF3-HLF4.3.2.3 11q23/KMT2A Gene Rearrangements; 4.3.2.4 Near-Haploidy and Low Hypodiploidy; 4.3.2.5 Intrachromosomal Amplification of Chromosome 21 (iAMP21); 4.3.3 B-ALL Lacking Sentinel Chromosomal Rearrangements; 4.3.3.1 Ph-Like or BCR-ABL1-Like ALL; 4.3.3.2 CRLF2 Rearrangements and Janus Kinase Mutations in ALL; 4.3.3.3 DUX4 and ERG-Deregulated ALL; 4.3.3.4 Translocations Involving the IGH Locus; 4.3.3.5 PAX5 Rearrangements; MEF2D and ZNF384 Gene Fusions; ETV6-RUNX1-Like; 4.3.4 Secondary Genetic Alterations in BCP-ALL; 4.4 Genetic Rearrangements in T-Lineage ALL.
520 3 _aThis book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.
588 0 _aOnline resource; title from PDF title page (SpringerLink, viewed April 27, 2017).
650 7 _2embne
_aLeucemia
_9140673
700 1 _aVora, Ajay,
_eeditor literario
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-39708-5
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b02/2018
_dz
_e-
_zSI